[Pubmed] Antibody production capacity after COVID-19 vaccination in immune-mediated neuromuscular diseases under immunot

[RSS-Bot]

Rinsho Shinkeigaku. 2023 Feb 25. doi: 10.5692/clinicalneurol.cn-001825. Online ahead of print.

ABSTRACT

The post-vaccination antibody response in patients with immune-mediated neuromuscular diseases under immuno-suppressive therapy has not been sufficiently verified. The Japanese Society of Neurology has stated that coronavirus disease 2019 (COVID-19) vaccination should be given priority in patients with immunotherapy-associated neuromuscular diseases; however, data on antibody production to a novel mRNA vaccine are scarce in these patients. In this study, we aimed to measure residual antibody titers after the second dose and produced antibodies after the third dose of SARS-CoV-2 mRNA vaccine in 25 patients with neuromuscular diseases under immuno-suppressive therapy (disease group). We compared the disease group antibody titers with those of 829 healthy employees in our hospital (control group). The disease group included 17 patients with myasthenia gravis, 4 with multiple sclerosis, 3 with inflammatory muscle disease, and 1 with chronic inflammatory demyelinating polyneuropathies. Seven cases of the disease group showed negative antibody levels (

Source: https://pubmed.ncbi.nlm.nih.gov/3684308 ... t6+86293ac